| Citation: |
XIE Liye, FU Jiejun, LU Yi, ZHANG Jian. Novel Findings on Activation of PD1/PD-L1 that Contributes to Cancer Development and Metastasis[J]. Cancer Research on Prevention and Treatment, 2017, 44(6): 423-427. DOI: 10.3971/j.issn.1000-8578.2017.17.0087
|
Programmed cell death protein-1 (PD1) and programmed cell death protein-1 ligand 1 (PD-L1) act as important negative immune regulators. Combining PD1 receptors on T cells with their corresponding ligands PD-L1 on tumor cells can inhibit T cell activation and lead to tumor cell immune escape and resistance to conventional chemotherapy. In recent years, the drugs targeting PD1/PD-L1 monoclonal antibodies have achieved promising effects in various tumor types including non-small cell lung carcinoma and melanoma. They also dramatically improved poor prognosis and overall survival of some tumor patients. In this review, we will summerize the novel findings on the activation of PD1/PD-L1 in tumor occurrence, development and metastasis, as well as the updated clinical progress of using anti-PD1 or anti-PD-L1 in tumor immunotherapy.
| [1] |
Ishida Y, Agata Y, Shibahara K. et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11): 3887-95. https://www.ncbi.nlm.nih.gov/pubmed?term=%22The+EMBO+journal%22%5BJour%5D+AND+11%5Bvolume%5D+AND+3887%5Bpage%5D+AND+1992%5Bpdat%5D&cmd=detailssearch
|
| [2] |
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12): 1365-9. doi: 10.1038/70932
|
| [3] |
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800. https://mayoclinic.pure.elsevier.com/en/publications/tumor-associated-b7-h1-promotes-t-cell-apoptosis-a-potential-mech
|
| [4] |
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7): 1027-34. doi: 10.1084/jem.192.7.1027
|
| [5] |
Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients[J].Oncotarget, 2016, 7(17): 24269-83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029700/
|
| [6] |
Iraolagoitia XL, Spallanzani RG, Torres NI, et al. NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells[J]. J Immunol, 2016, 197(3): 953-61. doi: 10.4049/jimmunol.1502291
|
| [7] |
Liu H, Bakthavatsalam R, Meng Z, et al. PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice[J]. Transplant Proc, 2013, 45(5): 1853-5. doi: 10.1016/j.transproceed.2013.03.015
|
| [8] |
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001, 2(3): 261-8. doi: 10.1038/85330
|
| [9] |
Stempin CC, Motran CC, Aoki MP, et al. PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepatica infection[J]. Oncotarget, 2016, 7(47): 77721-31. https://www.researchgate.net/publication/309361654_PD-L2_negatively_regulates_Th1-mediated_immunopathology_during_Fasciola_hepatica_infection
|
| [10] |
Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost[J].Nature, 2014, 515(7528): 496-8. doi: 10.1038/515496a
|
| [11] |
Koh YW, Jeon YK, Yoon DH, et al. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma[J]. Tumour Biol, 2016, 37(6): 7507-14. doi: 10.1007/s13277-015-4622-5
|
| [12] |
Wang X, Sun Q, Liu Q, et al. CTC immune escape mediated by PD-L1[J]. Med Hypotheses, 2016, 93: 138-9. doi: 10.1016/j.mehy.2016.05.022
|
| [13] |
Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells[J]. Mol Oncol, 2015, 9(9): 1773-82. doi: 10.1016/j.molonc.2015.05.009
|
| [14] |
Aktas B, Bankfalvi A, Heubner M, et al. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(R), clinicopathological markers and tumor cell dissemination in the blood and bone marrow[J]. Mol Clin Oncol, 2013, 1(6): 1049-54.
|
| [15] |
Chen YY, Wang LB, Zhu HL, et al. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients[J]. Chin Med Sci J, 2013, 28(3): 147-51. doi: 10.1016/S1001-9294(13)60040-1
|
| [16] |
Zhou SL, Zhou ZJ, Hu ZQ, et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling[J]. Cancer Lett, 2015, 358(2): 124-35. doi: 10.1016/j.canlet.2014.11.044
|
| [17] |
Steele CW, Karim SA, Leach JD, et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma[J]. Cancer Cell, 2016, 29(6): 832-45. doi: 10.1016/j.ccell.2016.04.014
|
| [18] |
Trojan J, Sarrazin C. Complete response of hepatocellular carcinoma in a patient with end-stage liver disease treated with nivolumab: whishful thinking or possible?[J]. Am J Gastroenterol, 2016, 111(8): 1208-9. doi: 10.1002/hep.27443/full?scrollTo=references
|
| [19] |
Mehta A, Gupta A, Hannallah F, et al. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma[J]. Melanoma Res, 2016, 26(3): 319-20. doi: 10.1097/CMR.0000000000000251
|
| [20] |
Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(7): 976-83. doi: 10.1016/S1470-2045(16)30053-5
|
| [21] |
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1): 23-34. doi: 10.1056/NEJMoa1504030
|
| [22] |
Atkins MB, Philips GK. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)[J]. Expert Opin Emerg Drugs, 2016, 21(3): 243-54. doi: 10.1080/14728214.2016.1226798
|
| [23] |
Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma[J]. Nat Commun, 2016, 7: 12624. doi: 10.1038/ncomms12624
|
| [24] |
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528): 563-7. doi: 10.1038/nature14011
|
| [25] |
Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phaseⅡtrial[J].J Clin Oncol, 2013, 31(33): 4199-206. doi: 10.1200/JCO.2012.48.3685
|
| [26] |
Guo Z, Wang H, Meng F, et al. Combined trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer[J]. J Transl Med, 2015, 13: 247. doi: 10.1186/s12967-015-0613-y
|
| [27] |
Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy[J]. Immunotherapy, 2015, 7(9): 967-80. doi: 10.2217/imt.15.65
|
| [28] |
Sagiv-Barfi I, Kohrt HE, Czerwinski DK, et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK[J]. Proc Natl Acad Sci U S A, 2015, 112(9): E966-72. doi: 10.1073/pnas.1500712112
|
| [29] |
Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial[J]. Ann Oncol, 2017, 28(4): 874-81.] doi: 10.1093/annonc/mdx008
|
| [30] |
Mok T, Schmid P, Aren O, et al. 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC[J]. J Thorac Oncol, 2016, 11(4 Suppl): S140-1. https://www.ncbi.nlm.nih.gov/pubmed/?term=tremelimumab
|
| [31] |
Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J].Lancet Oncol, 2016, 17(7): 883-95. doi: 10.1016/S1470-2045(16)30098-5
|
| [32] |
Atezolizumab (Tecentriq) for bladder cancer and NSCLC[J].Med Lett Drugs Ther, 2017, 59(1515): e40-1.
|
| [33] |
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(10): 1374-85. doi: 10.1016/S1470-2045(16)30364-3
|
| [34] |
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-65. doi: 10.1016/S0140-6736(16)32517-X
|
| [35] |
Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-8. doi: 10.1158/1078-0432.CCR-16-1741
|
| [36] |
Allard B, Pommey S, Smyth MJ, et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs[J].Clin Cancer Res, 2013, 19(20): 5626-35. doi: 10.1158/1078-0432.CCR-13-0545
|
| [37] |
Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(25): 2969-79. doi: 10.1200/JCO.2016.66.9861
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: